Aug. 3 IPO action brief: Braveheart Bio's $300M deal leads the week, but retail access is unverified
Braveheart Bio leads a biotech-heavy US IPO week with a $15-$17 range and an expected Aug. 6 debut, while no mainstream retail allocation is publicly verified and NASN TECH is the live Hong Kong deadline.
August 3, 2026 is a regular NYSE trading day. The core session is scheduled for 9:30 a.m. to 4:00 p.m. ET, and the date is not on the 2026 holiday or early-close list. 1
Today's spotlight: Braveheart Bio (BRVE)
Status: Expected to price before its Nasdaq debut on August 6. Public calendar data shows 18.8 million shares at $15–$17, for an estimated $300 million deal. A separate IPO pricing date is not disclosed. 2
Minimum buy-in: Not available through a verified public retail allocation. Broker access: No public order window was verified through Robinhood, Fidelity, Schwab, E*TRADE, or Webull. If BRVE appears in an app after listing, that would be ordinary stock trading, not proof of IPO access.
Braveheart Bio is a clinical-stage biotech developing BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy, a disease in which the heart muscle becomes abnormally thick. The company says it plans global Phase 3 trials in obstructive and non-obstructive HCM. 3
Why it matters: this is the largest clearly sized deal on the current US calendar, but it remains a clinical-stage bet. The real test is whether global Phase 3 work confirms the earlier data.
One number: In a 42-patient Phase 2 obstructive-HCM study, the filing reports an 86% complete-response rate at Week 12 in one cohort. More than 300 people had been dosed globally by June 9, 2026. Hengrui, the Chinese partner, designed and ran the studies; they were not the planned global Phase 3 program. 3
The risk to monitor: Braveheart has no product revenue and depends on one lead candidate. Its filing reports a $14.28 million net loss in Q1 2026 and an $80.33 million accumulated deficit as of March 31, 2026. The next hard milestone is the planned Phase 3 start in the second half of 2026; delays or failed replication could change the story quickly. 3
Actionable now
No US IPO allocation met the public evidence bar for an open or 48-hour deadline window. The calendars show offerings but no mainstream-broker path; the NYSE filing page showed no filed deals on its August 3 update. 456
| Ticker | Price range | Minimum buy-in | Deadline | Verified brokers | Status |
|---|---|---|---|---|---|
| None verified | — | — | No public US allocation window found | None publicly verified | Watch only |
BRVE, ATTO, and VOGX are listing-watch names until a public allocation notice says otherwise.
Market pulse
- No public oversubscription multiple or retail-allocation confirmation was disclosed in the accepted sources. A $300 million deal can be important without telling you whether an ordinary brokerage customer can buy at the IPO price.
HK desk
NASN TECH (2261) is open and closing soon. The offer range is HK$10.42–HK$11.18 for a 100-share board lot. That makes the face-value minimum HK$1,042 at the low end, before fees. The noon Hong Kong deadline on August 4 converts to 04:00 on August 4 in this brief’s display time. Listing is August 7. 910
NASN TECH develops brake-by-wire systems for intelligent-driving vehicles. ET Net says its customers are mainly Chinese automakers and that it ranked among China’s top three domestic providers by 2025 sales volume. Phillip Securities corroborates the terms and dates. This is a Hong Kong public offer, not a US broker allocation. 1011
On the radar: August 3–17
The calendar gives no separate pricing date, so none is inferred.
| Deal | Pricing date | Expected listing | Terms | Why watch |
|---|---|---|---|---|
| Attovia Therapeutics (ATTO) | Not separately disclosed | Aug. 5 | 12.5M shares at $15–$17; est. $200M | Phase 1 immune-disease biotech with no products on the market or product-sales revenue. 7 |
| Braveheart Bio (BRVE) | Not separately disclosed | Aug. 6 | 18.8M shares at $15–$17; est. $300M | Largest deal in the current calendar; Phase 3 HCM execution is the test. 2 |
| Vogenx (VOGX) | Not separately disclosed | Aug. 6 | 6.25M shares at $11–$13; est. $75M | Phase 2 metabolic biotech; its lead candidate has never produced revenue. 8 |
Market information only, not investment advice. IPO terms, dates, and access can change before a final prospectus, pricing, or listing.
References
- 1NYSE holidays and trading hours
nyse.com
- 2Braveheart Bio IPO profile
iposcoop.com
- 3Braveheart Bio Form S-1
sec.gov
- 4IPO Calendar 2026
renaissancecapital.com
- 5IPOscoop IPO calendar
iposcoop.com
- 6NYSE IPO filings
nyse.com
- 7Attovia Therapeutics IPO profile
iposcoop.com
- 8Vogenx IPO profile
iposcoop.com
- 9ET Net IPO dashboard
etnet.com.hk
- 10NASN TECH IPO detail
etnet.com.hk
- 11Phillip Securities IPO information
poems.com.hk
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.